Tuberculosis (TB) is a highly contagious lung disease caused by infection with Mycobacterium tuberculosis.

Upon tuberculosis infection, the host immune responses such as cell mediated immunity and delayed type hypersensitivity occurs and during this process T cell is the main control of the infections.

Most common treatment is combination of four drugs, isoniazid, rifampin, ethambutol, and pyrazinamide, daily for two months, then continued without pyrazinamide for four to seven months,

However, standard treatment includes side effects such as liver toxicity, leukopenia, ototoxicity, peripheral neuritis, and arthralgia. Therefore, drug with safer profile is in need.

Considering the systemic side effects from multidrug oral administration, drug that can shorten the long treatment period (more than 6 months) and reduce the number of antituberculosis medications (4-6 types) taken is in need.